Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

Persistent microbial dysbiosis in preterm premature rupture of membranes from onset until delivery
Baldwin, Elizabeth , Walther-António, Marina , Maclean, Allison, Gohl, Daryl M. , Beckman, Kenneth B. , White, Bryan A. , Creedon, Douglas J., Baldwin, Elizabeth A, Chia, Nicholas , Chen, Jun , Chia, Nicholas , Walther-Antonio, Marina

Mayo Clinic

PeerJ | November 26, 2015 | Volume: 3 | Issue: No issue available | Pages: e1398

10.7717/peerj.1398 | PMID 26644969 Get It

Background. Preterm Premature Rupture of Membranes (PPROM) is a major leading cause of preterm births. While the cause for PPROM remains unidentified, it is anticipated to be due to subclinical infection, since a large proportion of PPROM patients display signs of chorioamnionitis. Since subclinical infections can be facilitated by dysbiosis, our goal was to characterize the vaginal microbiome and amniotic fluid discharge upon PPROM, through latency antibiotic treatment, and until delivery, to detect the presence of pathogens, microbiota alteration, and microbial response to treatment. Methods. Enrolled subjects (15) underwent routine institutional antenatal care for PPROM, including the administration of latency antibiotics. Serial vaginal swabs were obtained from diagnosis of PPROM through delivery and the sequencing of the V3–V5 region of the 16S rRNA gene was performed for all collected samples. Results. The results show that Lactobacilli species were markedly decreased when compared to vaginal swabs collected from uncomplicated pregnancy subjects with a matched gestational time. Prevotella and Peptoniphilus were the most prevalent taxa in PPROM subjects at presentation. The vaginal microbiome of the PPROM subjects varied substantially intra- and inter-subjects. Several taxa were found to be significantly reduced during and after the antibiotic treatment: Weeksella , Lachnospira , Achromobacter , and Pediococcus . In contrast, Peptostreptococcus and Tissierellaceae ph2 displayed a significant increase after the antibiotic treatment. However, the relative abundance of Lactobacillus , Prevotella , and Peptoniphilus was not substantially impacted during the hospitalization of the PPROM subjects. The deficiency of Lactobacillus , and constancy of known pathogenic species, such as Prevotella and Peptoniphilus during and after antibiotics, highlights the persistent dysbiosis and warrants further investigation into mitigating approaches. Discussion. PPROM is responsible for one third of all preterm births. It is thought that subclinical infection is a crucial factor in the pathophysiology of PPROM because 25–40% of patients present signs of chorioamnionitis on amniocentesis. Here we sought to directly assess the bacterial content of the vagina and leaking amniotic fluid of subjects at presentation, throughout treatment and up until delivery, in order to search for common pathogens, microbiota changes, and microbial response to latency antibiotic treatment. We have found that the vaginal microbiome of PPROM subjects is highly variable and displays significant changes to treatment. However, the unchanging deficiency of Lactobacillus , and persistence of known pathogenic species, such as Prevotella and Peptoniphilus from presentation, through antibiotic treatment and up until delivery, highlights the persistent dysbiosis and warrants further investigation into mitigating approaches.
Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
McVary, Kevin T. , Gange, Steven, Gittelman, Marc , Patel, Kalpesh, Levin, Richard, Rousseau, Michael, Beahrs, J. Randolf, Kaminetsky, Jed , Cowan, Barrett E., Cantrill, Christopher H., Mynderse, Lance A. , Ulchaker, James, Larson, Thayne R., Dixon, Christopher , Roehrborn, Claus G. , Goldberg, Kenneth A. , Shore, Neal D.

Mayo Clinic

Journal of Urology | November 22, 2015 | Volume: 195 | Issue: 5 | Pages: 1529-1538

10.1016/j.juro.2015.10.181 | PMID 26614889 Get It

Is Monitoring of Total Beam-On Time a Sufficient Measure of Patient Radiation Exposure in the Interventional Cardiology Laboratories?
Fetterly, Kenneth A.

Mayo Clinic

American Journal of Roentgenology | November 20, 2015 | Volume: 205 | Issue: 6 | Pages: W567-W567

10.2214/ajr.15.14991 | PMID 26587945 Get It

Automated Three-Dimensional Reconstruction of the Left Ventricle From Multiple-Axis Echocardiography
Krishnan, Navaneetha, Song, Zeying, Hoffmann, Kenneth R., Bëlohlávek, Marek , McMahon, Eileen M. , Borazjani, Iman , Borazjani, Iman

Mayo Clinic

Journal of Biomechanical Engineering | November 9, 2015 | Volume: 138 | Issue: 1 | Pages: No page available

10.1115/1.4031977 | PMID 26548948 Get It

Two-dimensional echocardiography (echo) is the method of choice for noninvasive evaluation of the left ventricle (LV) function owing to its low cost, fast acquisition time, and high temporal resolution. However, it only provides the LV boundaries in discrete 2D planes, and the 3D LV geometry needs to be reconstructed from those planes to quantify LV wall motion, acceleration, and strain, or to carry out flow simulations. An automated method is developed for the reconstruction of the 3D LV endocardial surface using echo from a few standard cross sections, in contrast with the previous work that has used a series of 2D scans in a linear or rotational manner for 3D reconstruction. The concept is based on a generalized approach so that the number or type (long-axis (LA) or short-axis (SA)) of sectional data is not constrained. The location of the cross sections is optimized to minimize the difference between the reconstructed and measured cross sections, and the reconstructed LV surface is meshed in a standard format. Temporal smoothing is implemented to smooth the motion of the LV and the flow rate. This software tool can be used with existing clinical 2D echo systems to reconstruct the 3D LV geometry and motion to quantify the regional akinesis/dyskinesis, 3D strain, acceleration, and velocities, or to be used in ventricular flow simulations.
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, Jasvinder A. , Bridges, S. Louis , Bannuru, Raveendhara R. , Sullivan, Matthew C. , Vaysbrot, Elizaveta E., McNaughton, Christine, Osani, Mikala C. , Parks, Deborah, Kavanaugh, Arthur, O’Dell, James R., Leong, Amye , Matteson, Eric L. , Drevlow, Barbara E., Ginsberg, Seth, Grober, James, Clair, E. William St. , Tindall, Elizabeth A., Miller, Amy S., Saag, Kenneth G. , Akl, Elie A. , Shmerling, Robert H. , Curtis, Jeffrey R. , Furst, Daniel E. , King, Charles M. , Schousboe, John T. , Grober, James, McAlindon, Timothy E. , Singh, Jasvinder A , Bannuru, Raveendhara R

Mayo Clinic

Arthritis Care & Research | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 1-25

10.1002/acr.22783 | PMID 26545825 Get It

ObjectiveTo develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA).MethodsWe conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.ResultsThe guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat‐to‐target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional.ConclusionThis RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision‐making process taking into account patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, Jasvinder A. , Bridges, S. Louis , Bannuru, Raveendhara R. , Sullivan, Matthew C. , Vaysbrot, Elizaveta E., McNaughton, Christine, Osani, Mikala C. , Parks, Deborah, Kavanaugh, Arthur, O’Dell, James R., Leong, Amye , Matteson, Eric L. , Drevlow, Barbara E., Ginsberg, Seth, Grober, James, Clair, E. William St. , Tindall, Elizabeth A., Miller, Amy S., McAlindon, Timothy E. , Saag, Kenneth G. , Akl, Elie A. , Shmerling, Robert H. , Curtis, Jeffrey R. , Furst, Daniel E. , King, Charles M. , Schousboe, John T. , Grober, James, Singh, Jasvinder A , Bannuru, Raveendhara R

Mayo Clinic

Arthritis & Rheumatology | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 1-26

10.1002/art.39480 | PMID 26545940 Get It

Objective To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat‐to‐target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional. Conclusion This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision‐making process taking into account patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
24‐Year‐Old Woman with Recent Onset Back Pain
Spengel, Kenneth C., Aleff, Patrice C. Abell, Rivera, Michael , Wald, John T. , Abell Aleff, Patrice C, Giannini, Caterina

Mayo Clinic

Brain Pathology | November 3, 2015 | Volume: 25 | Issue: 6 | Pages: 786-787

10.1111/bpa.12324 | PMID 26526948 Get It

Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia
Kong, Jianping , Sai, Hong, Crissey, Mary Ann S. , Jhala, Nirag, Ginsberg, Gregory G. , Rustgi, Anil K. , Wang, Timothy C. , Falk, Gary W. , Abrams, Julian A , Nakagawa, Hiroshi , Wang, Kenneth , Lynch, John Patrick

Mayo Clinic

Oncotarget | October 25, 2015 | Volume: 6 | Issue: 32 | Pages: 32980-33005

10.18632/oncotarget.5431 | PMID 26460825 Get It

MDS research criteria for prodromal Parkinson's disease
Berg, Daniela , Bloem, Bastiaan R. , Dubois, Bruno, Gasser, Thomas , Halliday, Glenda M. , Joseph, Lawrence , Lang, Anthony E. , Liepelt‐Scarfone, Inga , Litvan, Irene , Marek, Kenneth , Oertel, Wolfgang H. , Olanow, C. Warren , Deuschl, Günther , Postuma, Ronald B. , Adler, Charles H. , Chan, Piu , Goetz, Christopher G. , Obeso, Jose Angel , Poewe, Werner H , Stern, Matthew , Halliday, Glenda , Lang, Anthony E , Deuschl, Günther , Litvan, Irene

Mayo Clinic

Movement Disorders | October 16, 2015 | Volume: 30 | Issue: 12 | Pages: 1600-1611

10.1002/mds.26431 | PMID 26474317 Get It

ABSTRACT This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease‐modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available. © 2015 International Parkinson and Movement Disorder Society
MDS clinical diagnostic criteria for Parkinson's disease
Berg, Daniela , Olanow, C. Warren , Oertel, Wolfgang H. , Marek, Kenneth , Litvan, Irene , Lang, Anthony E. , Halliday, Glenda M. , Gasser, Thomas , Dubois, Bruno, Bloem, Bastiaan R. , Deuschl, Günther , Postuma, Ronald B. , Stern, Matthew , Poewe, Werner H , Obeso, Jose Angel , Goetz, Christopher G. , Chan, Piu , Adler, Charles H. , Halliday, Glenda , Lang, Anthony E , Deuschl, Günther , Litvan, Irene

Mayo Clinic

Movement Disorders | October 16, 2015 | Volume: 30 | Issue: 12 | Pages: 1591-1601

10.1002/mds.26424 | PMID 26474316 Get It

AbstractThis document presents the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis. The benchmark for these criteria is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise in PD diagnosis. Although motor abnormalities remain central, increasing recognition has been given to nonmotor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis). Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity). The Movement Disorder Society criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, the Movement Disorder Society criteria will need continuous revision to accommodate these advances. © 2015 International Parkinson and Movement Disorder Society